Status:
COMPLETED
VX-950 and Peginterferon for Hepatitis C
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Hepatitis C
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.
Eligibility Criteria
Inclusion
- infected with Hepatitis C virus
Exclusion
- contraindications to peginterferon therapy
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00251199
Start Date
October 1 2005
End Date
March 1 2006
Last Update
December 21 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Call for information
Homburg/Saar, Germany
2
Call for information
Amsterdam, Netherlands